138187-95-8

Basic information

• Product Name: 1-methyl-6-(2-nitrophenyl)pyrazolo[3,4-d][1,3]oxazin-4(1H)-one
• CAS NO: 138187-95-8
• Molecular Formula: C₁₂H₈N₄O₄
• Molecular Weight: 272.2163
• Mol File: 138187-95-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 465.9°C at 760 mmHg
• Flash Point: 235.6°C
• Density: 1.61g/cm³
• Vapor Pressure: 7.41E-09mmHg at 25°C
• Refractive Index: 1.738
• CAS DataBase Reference: 1-methyl-6-(2-nitrophenyl)pyrazolo[3,4-d][1,3]oxazin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-6-(2-nitrophenyl)pyrazolo[3,4-d][1,3]oxazin-4(1H)-one(138187-95-8)
• EPA Substance Registry System: 1-methyl-6-(2-nitrophenyl)pyrazolo[3,4-d][1,3]oxazin-4(1H)-one(138187-95-8)

Safety Data

• Hazardous Substances Data: 138187-95-8(Hazardous Substances Data)

Upstream product

• 138188-06-4 N-(1-methyl-4-carboxypyrazol-5-yl)-2-nitrobenzamide 
• 104907-76-8 1-methyl-5-(2-nitro-benzoylamino)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 
• 610-14-0 2-nitrobenzyl chloride 
• 271778-17-7 5-[bis(2-nitro-benzoyl)-amino]-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 

Downstream Products

• 548775-43-5 C₁₂H₁₂N₆O₄ 

Relevant articles and documents

Inhibitors of the tissue factor/factor VIIa-induced coagulation: Synthesis and in vitro evaluation of novel 2-aryl substituted pyrido[3,4-d][1,3]-, pyrido[2,3-d][1,3]-, pyrazino[2,3-d][1,3]-, pyrimido[4,5-d][1,3]-, pyrazolo[3,4-d][1,3]-, thieno[3,2-d][1,3]- and thieno[2,3-d][1,3]-oxazin-4-ones

The synthesis of a series of 2-aryl substituted hetero annulated 1,3-oxazin-4-ones and their evaluation as specific inhibitors of the tissue factor (TF)/factor VIIa (FVIIa)-induced pathway of coagulation is reported. Inhibitory activities (IC50 values) in the range 0.64 to >40μM on the activation of factor X (FX) by the TF/FVIIa complex were found for compounds having one or two electronegative substituents such as F and NO2 in the 2-aryl substituent. Some of the compounds showed a selectivity ratio towards FX and thrombin of >50, thus being similar in specificity to 2-aryl substituted 4H-3,1-benzoxazin-4-ones described as potential drugs for oral antithrombotic treatment without side effects, such as bleeding, which is observed especially with thrombin inhibitors. Copyright (C) 2000 Elsevier Science Ltd.